Patents by Inventor Kutralanathan Renganathan

Kutralanathan Renganathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions And Methods For Macular Degeneration
    Publication number: 20160108114
    Abstract: The present invention pertains to methods of inhibiting angiogenesis (e.g., ocular angiogenesis choroidal neovasculariztion) in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of 5 oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual.
    Type: Application
    Filed: October 23, 2015
    Publication date: April 21, 2016
    Inventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Renganathan
  • Compositions And Methods For Macular Degeneration
    Publication number: 20120230996
    Abstract: The present invention pertains to methods of inhibiting angiogenesis (e.g., ocular angiogenesis choroidal neovasculariztion) in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of 5 oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual.
    Type: Application
    Filed: February 9, 2012
    Publication date: September 13, 2012
    Applicant: The Cleveland Clinic Foundation and Case Western Reserve University
    Inventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Renganathan
  • COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION
    Publication number: 20100143380
    Abstract: The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual.
    Type: Application
    Filed: July 23, 2007
    Publication date: June 10, 2010
    Inventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Renganathan